Global Long-acting Somatostatin Analogues (LA SSAs) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 85

Published Date: 11 Oct 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

Long-acting somatostatin analogues (LA SSAs) are synthetic derivatives of the natural hormone somatostatin, designed to mimic its effects while offering extended half-lives for prolonged therapeutic action. These medications primarily function to inhibit the secretion of growth hormone and other hormones, making them particularly effective in treating conditions such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.

According to our (Global Info Research) latest study, the global Long-acting Somatostatin Analogues (LA SSAs) market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

The market for long-acting somatostatin analogues (LA SSAs) is experiencing robust growth, driven by the rising prevalence of hormone-related disorders such as acromegaly and neuroendocrine tumors. As awareness of these conditions increases and diagnostic capabilities improve, more patients are being identified and treated with LA SSAs.

Recent advancements in formulation and delivery methods have also positively impacted the LA SSA market. The development of long-acting formulations allows for less frequent dosing, which enhances patient compliance and satisfaction. Additionally, ongoing research into new therapeutic applications of LA SSAs—such as their potential use in treating other endocrine disorders—expands their market appeal and encourages pharmaceutical companies to invest in further research and development.

Furthermore, the increasing focus on personalized medicine is shaping the market landscape for LA SSAs. Healthcare providers are increasingly tailoring treatments based on individual patient profiles, making the specific and targeted action of LA SSAs particularly valuable. As clinical guidelines continue to evolve and integrate LA SSAs into broader treatment protocols, the market is expected to grow steadily, with an expanding range of indications and improved therapeutic options for patients with hormone-related disorders.

This report is a detailed and comprehensive analysis for global Long-acting Somatostatin Analogues (LA SSAs) market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Long-acting Somatostatin Analogues (LA SSAs) market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Long-acting Somatostatin Analogues (LA SSAs) market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Long-acting Somatostatin Analogues (LA SSAs) market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Long-acting Somatostatin Analogues (LA SSAs) market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Long-acting Somatostatin Analogues (LA SSAs)
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Long-acting Somatostatin Analogues (LA SSAs) market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Novartis, Ipsen, Recordati Rare Diseases, Chiesi Farmaceutici S.p.A, Teva, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Long-acting Somatostatin Analogues (LA SSAs) market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Injections
    Oral Capsules

Market segment by Application
    Neuroendocrine Tumors
    Acromegaly
    Other

Major players covered
    Novartis
    Ipsen
    Recordati Rare Diseases
    Chiesi Farmaceutici S.p.A
    Teva

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Long-acting Somatostatin Analogues (LA SSAs) product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Long-acting Somatostatin Analogues (LA SSAs), with price, sales quantity, revenue, and global market share of Long-acting Somatostatin Analogues (LA SSAs) from 2019 to 2024.
Chapter 3, the Long-acting Somatostatin Analogues (LA SSAs) competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Long-acting Somatostatin Analogues (LA SSAs) breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Long-acting Somatostatin Analogues (LA SSAs) market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Long-acting Somatostatin Analogues (LA SSAs).
Chapter 14 and 15, to describe Long-acting Somatostatin Analogues (LA SSAs) sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Injections
        1.3.3 Oral Capsules
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Neuroendocrine Tumors
        1.4.3 Acromegaly
        1.4.4 Other
    1.5 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size & Forecast
        1.5.1 Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (2019-2030)
        1.5.3 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Novartis
        2.1.1 Novartis Details
        2.1.2 Novartis Major Business
        2.1.3 Novartis Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        2.1.4 Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Novartis Recent Developments/Updates
    2.2 Ipsen
        2.2.1 Ipsen Details
        2.2.2 Ipsen Major Business
        2.2.3 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        2.2.4 Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Ipsen Recent Developments/Updates
    2.3 Recordati Rare Diseases
        2.3.1 Recordati Rare Diseases Details
        2.3.2 Recordati Rare Diseases Major Business
        2.3.3 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        2.3.4 Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Recordati Rare Diseases Recent Developments/Updates
    2.4 Chiesi Farmaceutici S.p.A
        2.4.1 Chiesi Farmaceutici S.p.A Details
        2.4.2 Chiesi Farmaceutici S.p.A Major Business
        2.4.3 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        2.4.4 Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.4.5 Chiesi Farmaceutici S.p.A Recent Developments/Updates
    2.5 Teva
        2.5.1 Teva Details
        2.5.2 Teva Major Business
        2.5.3 Teva Long-acting Somatostatin Analogues (LA SSAs) Product and Services
        2.5.4 Teva Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.5.5 Teva Recent Developments/Updates

3 Competitive Environment: Long-acting Somatostatin Analogues (LA SSAs) by Manufacturer
    3.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturer (2019-2024)
    3.3 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Long-acting Somatostatin Analogues (LA SSAs) by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Long-acting Somatostatin Analogues (LA SSAs) Manufacturer Market Share in 2023
        3.4.3 Top 6 Long-acting Somatostatin Analogues (LA SSAs) Manufacturer Market Share in 2023
    3.5 Long-acting Somatostatin Analogues (LA SSAs) Market: Overall Company Footprint Analysis
        3.5.1 Long-acting Somatostatin Analogues (LA SSAs) Market: Region Footprint
        3.5.2 Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Type Footprint
        3.5.3 Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Long-acting Somatostatin Analogues (LA SSAs) Market Size by Region
        4.1.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Region (2019-2030)
        4.1.2 Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2019-2030)
        4.1.3 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Region (2019-2030)
    4.2 North America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030)
    4.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030)
    4.4 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030)
    4.5 South America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030)
    4.6 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2030)
    5.2 Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Type (2019-2030)
    5.3 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2030)
    6.2 Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Application (2019-2030)
    6.3 Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2019-2030)

7 North America
    7.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2030)
    7.2 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2030)
    7.3 North America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
        7.3.1 North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2030)
        7.3.2 North America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2030)
    8.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2030)
    8.3 Europe Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
        8.3.1 Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2030)
        8.3.2 Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Market Size by Region
        9.3.1 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 South Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2030)
    10.2 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2030)
    10.3 South America Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
        10.3.1 South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2030)
        10.3.2 South America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Market Size by Country
        11.3.1 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Long-acting Somatostatin Analogues (LA SSAs) Market Drivers
    12.2 Long-acting Somatostatin Analogues (LA SSAs) Market Restraints
    12.3 Long-acting Somatostatin Analogues (LA SSAs) Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Long-acting Somatostatin Analogues (LA SSAs) and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Long-acting Somatostatin Analogues (LA SSAs)
    13.3 Long-acting Somatostatin Analogues (LA SSAs) Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Long-acting Somatostatin Analogues (LA SSAs) Typical Distributors
    14.3 Long-acting Somatostatin Analogues (LA SSAs) Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Novartis Basic Information, Manufacturing Base and Competitors
 Table 4. Novartis Major Business
 Table 5. Novartis Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 6. Novartis Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 7. Novartis Recent Developments/Updates
 Table 8. Ipsen Basic Information, Manufacturing Base and Competitors
 Table 9. Ipsen Major Business
 Table 10. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 11. Ipsen Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 12. Ipsen Recent Developments/Updates
 Table 13. Recordati Rare Diseases Basic Information, Manufacturing Base and Competitors
 Table 14. Recordati Rare Diseases Major Business
 Table 15. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 16. Recordati Rare Diseases Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 17. Recordati Rare Diseases Recent Developments/Updates
 Table 18. Chiesi Farmaceutici S.p.A Basic Information, Manufacturing Base and Competitors
 Table 19. Chiesi Farmaceutici S.p.A Major Business
 Table 20. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 21. Chiesi Farmaceutici S.p.A Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 22. Chiesi Farmaceutici S.p.A Recent Developments/Updates
 Table 23. Teva Basic Information, Manufacturing Base and Competitors
 Table 24. Teva Major Business
 Table 25. Teva Long-acting Somatostatin Analogues (LA SSAs) Product and Services
 Table 26. Teva Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 27. Teva Recent Developments/Updates
 Table 28. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Manufacturer (2019-2024) & (K Units)
 Table 29. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Manufacturer (2019-2024) & (USD Million)
 Table 30. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Manufacturer (2019-2024) & (US$/Unit)
 Table 31. Market Position of Manufacturers in Long-acting Somatostatin Analogues (LA SSAs), (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 32. Head Office and Long-acting Somatostatin Analogues (LA SSAs) Production Site of Key Manufacturer
 Table 33. Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Type Footprint
 Table 34. Long-acting Somatostatin Analogues (LA SSAs) Market: Company Product Application Footprint
 Table 35. Long-acting Somatostatin Analogues (LA SSAs) New Market Entrants and Barriers to Market Entry
 Table 36. Long-acting Somatostatin Analogues (LA SSAs) Mergers, Acquisition, Agreements, and Collaborations
 Table 37. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
 Table 38. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Region (2019-2024) & (K Units)
 Table 39. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Region (2025-2030) & (K Units)
 Table 40. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2019-2024) & (USD Million)
 Table 41. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2025-2030) & (USD Million)
 Table 42. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Region (2019-2024) & (US$/Unit)
 Table 43. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Region (2025-2030) & (US$/Unit)
 Table 44. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2024) & (K Units)
 Table 45. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2025-2030) & (K Units)
 Table 46. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Type (2019-2024) & (USD Million)
 Table 47. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Type (2025-2030) & (USD Million)
 Table 48. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2019-2024) & (US$/Unit)
 Table 49. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2025-2030) & (US$/Unit)
 Table 50. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2024) & (K Units)
 Table 51. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2025-2030) & (K Units)
 Table 52. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Application (2019-2024) & (USD Million)
 Table 53. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Application (2025-2030) & (USD Million)
 Table 54. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2019-2024) & (US$/Unit)
 Table 55. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2025-2030) & (US$/Unit)
 Table 56. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2024) & (K Units)
 Table 57. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2025-2030) & (K Units)
 Table 58. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2024) & (K Units)
 Table 59. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2025-2030) & (K Units)
 Table 60. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2024) & (K Units)
 Table 61. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2025-2030) & (K Units)
 Table 62. North America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2024) & (USD Million)
 Table 63. North America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2025-2030) & (USD Million)
 Table 64. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2024) & (K Units)
 Table 65. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2025-2030) & (K Units)
 Table 66. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2024) & (K Units)
 Table 67. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2025-2030) & (K Units)
 Table 68. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2024) & (K Units)
 Table 69. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2025-2030) & (K Units)
 Table 70. Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2024) & (USD Million)
 Table 71. Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2025-2030) & (USD Million)
 Table 72. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2024) & (K Units)
 Table 73. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2025-2030) & (K Units)
 Table 74. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2024) & (K Units)
 Table 75. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2025-2030) & (K Units)
 Table 76. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Region (2019-2024) & (K Units)
 Table 77. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Region (2025-2030) & (K Units)
 Table 78. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2019-2024) & (USD Million)
 Table 79. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Region (2025-2030) & (USD Million)
 Table 80. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2024) & (K Units)
 Table 81. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2025-2030) & (K Units)
 Table 82. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2024) & (K Units)
 Table 83. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2025-2030) & (K Units)
 Table 84. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2024) & (K Units)
 Table 85. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2025-2030) & (K Units)
 Table 86. South America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2024) & (USD Million)
 Table 87. South America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2025-2030) & (USD Million)
 Table 88. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2019-2024) & (K Units)
 Table 89. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Type (2025-2030) & (K Units)
 Table 90. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2019-2024) & (K Units)
 Table 91. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Application (2025-2030) & (K Units)
 Table 92. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2019-2024) & (K Units)
 Table 93. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity by Country (2025-2030) & (K Units)
 Table 94. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2019-2024) & (USD Million)
 Table 95. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Country (2025-2030) & (USD Million)
 Table 96. Long-acting Somatostatin Analogues (LA SSAs) Raw Material
 Table 97. Key Manufacturers of Long-acting Somatostatin Analogues (LA SSAs) Raw Materials
 Table 98. Long-acting Somatostatin Analogues (LA SSAs) Typical Distributors
 Table 99. Long-acting Somatostatin Analogues (LA SSAs) Typical Customers


List of Figures
 Figure 1. Long-acting Somatostatin Analogues (LA SSAs) Picture
 Figure 2. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Type in 2023
 Figure 4. Injections Examples
 Figure 5. Oral Capsules Examples
 Figure 6. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application in 2023
 Figure 8. Neuroendocrine Tumors Examples
 Figure 9. Acromegaly Examples
 Figure 10. Other Examples
 Figure 11. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 12. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 13. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity (2019-2030) & (K Units)
 Figure 14. Global Long-acting Somatostatin Analogues (LA SSAs) Price (2019-2030) & (US$/Unit)
 Figure 15. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Manufacturer in 2023
 Figure 16. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Manufacturer in 2023
 Figure 17. Producer Shipments of Long-acting Somatostatin Analogues (LA SSAs) by Manufacturer Sales ($MM) and Market Share (%): 2023
 Figure 18. Top 3 Long-acting Somatostatin Analogues (LA SSAs) Manufacturer (Revenue) Market Share in 2023
 Figure 19. Top 6 Long-acting Somatostatin Analogues (LA SSAs) Manufacturer (Revenue) Market Share in 2023
 Figure 20. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Region (2019-2030)
 Figure 21. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Region (2019-2030)
 Figure 22. North America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 23. Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 24. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 25. South America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 26. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 27. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Type (2019-2030)
 Figure 28. Global Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Type (2019-2030)
 Figure 29. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Type (2019-2030) & (US$/Unit)
 Figure 30. Global Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Application (2019-2030)
 Figure 31. Global Long-acting Somatostatin Analogues (LA SSAs) Revenue Market Share by Application (2019-2030)
 Figure 32. Global Long-acting Somatostatin Analogues (LA SSAs) Average Price by Application (2019-2030) & (US$/Unit)
 Figure 33. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Type (2019-2030)
 Figure 34. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Application (2019-2030)
 Figure 35. North America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Country (2019-2030)
 Figure 36. North America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Country (2019-2030)
 Figure 37. United States Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 38. Canada Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 39. Mexico Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 40. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Type (2019-2030)
 Figure 41. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Application (2019-2030)
 Figure 42. Europe Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Country (2019-2030)
 Figure 43. Europe Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Country (2019-2030)
 Figure 44. Germany Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 45. France Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 46. United Kingdom Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 47. Russia Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 48. Italy Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 49. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Type (2019-2030)
 Figure 50. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Application (2019-2030)
 Figure 51. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Region (2019-2030)
 Figure 52. Asia-Pacific Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Region (2019-2030)
 Figure 53. China Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 54. Japan Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 55. South Korea Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 56. India Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 57. Southeast Asia Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 58. Australia Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 59. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Type (2019-2030)
 Figure 60. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Application (2019-2030)
 Figure 61. South America Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Country (2019-2030)
 Figure 62. South America Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Country (2019-2030)
 Figure 63. Brazil Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 64. Argentina Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 65. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Type (2019-2030)
 Figure 66. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Application (2019-2030)
 Figure 67. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Sales Quantity Market Share by Country (2019-2030)
 Figure 68. Middle East & Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value Market Share by Country (2019-2030)
 Figure 69. Turkey Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 70. Egypt Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 71. Saudi Arabia Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 72. South Africa Long-acting Somatostatin Analogues (LA SSAs) Consumption Value (2019-2030) & (USD Million)
 Figure 73. Long-acting Somatostatin Analogues (LA SSAs) Market Drivers
 Figure 74. Long-acting Somatostatin Analogues (LA SSAs) Market Restraints
 Figure 75. Long-acting Somatostatin Analogues (LA SSAs) Market Trends
 Figure 76. Porters Five Forces Analysis
 Figure 77. Manufacturing Cost Structure Analysis of Long-acting Somatostatin Analogues (LA SSAs) in 2023
 Figure 78. Manufacturing Process Analysis of Long-acting Somatostatin Analogues (LA SSAs)
 Figure 79. Long-acting Somatostatin Analogues (LA SSAs) Industrial Chain
 Figure 80. Sales Channel: Direct to End-User vs Distributors
 Figure 81. Direct Channel Pros & Cons
 Figure 82. Indirect Channel Pros & Cons
 Figure 83. Methodology
 Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Novartis
Ipsen
Recordati Rare Diseases
Chiesi Farmaceutici S.p.A
Teva

Related Reports

Global Long-acting Somatostatin Analogues (LA SSAs) Supply, Demand and Key Producers, 2024-2030

Global Long-acting Somatostatin Analogues (LA SSAs) Supply, Demand and Key Producers, 2024-2030

date 11 Oct 2024

date Pharma & Healthcare

Long-acting somatostatin analogues (LA SSAs) are synthetic derivatives of the natural hormone somatostatin, designed to mimic its effects while offering extended half-lives for prolonged therapeutic action. These medications primarily function to inhibit the secretion of growth hormone and other hormones, making them particularly effective in treating conditions such as acromegaly, neuroendocrine tumors, and certain gastrointestinal disorders.

Product Tags

Long-acting Somatostatin Analogues (LA SSAs)

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>